Associations between pretreatment factors and response to imatinib mesylate
| Characteristic . | No. . | No. responding (%) . | P . | Median survival, mo . | P . |
|---|---|---|---|---|---|
| Age, y | |||||
| < 60 | 48 | 21 (44) | .09 | 6.0 | .86 |
| ≥ 60 | 27 | 18 (67) | |||
| Splenomegaly, cm bcm | |||||
| ≤ 5 | 40 | 21 (53) | .62 | 7.1 | .46 |
| > 5 | 28 | 17 (61) | 7.5 | ||
| Hemoglobin, g/dL | |||||
| < 10 | 38 | 21 (55) | .65 | 5.2 | .49 |
| ≥ 10 | 37 | 18 (49) | 5.2 | ||
| White blood cells, × 109/L | |||||
| < 30 | 38 | 22 (58) | .36 | 9.0 | .08 |
| ≥ 30 | 37 | 17 (46) | 5.4 | ||
| Platelets, × 109/L | |||||
| ≤ 50 | 25 | 10 (40) | .15 | 4.2 | .02 |
| > 50 | 50 | 29 (58) | 7.6 | ||
| % Peripheral blood blasts | |||||
| < 50 | 48 | 30 (63) | .02 | 7.6 | .18 |
| ≥ 50 | 27 | 9 (33) | 6.0 | ||
| % Bone marrow blasts | |||||
| < 50 | 35 | 20 (57) | .49 | 7.2 | .28 |
| ≥ 50 | 40 | 19 (48) | 6.2 | ||
| Blast morphology | |||||
| Lymphoid | 10 | 3 (30) | .18 | 6.8 | .20 |
| Nonlymphoid | 65 | 36 (55) | 6.5 | ||
| Time from diagnosis to blast phase, mo | |||||
| < 12 | 17 | 8 (47) | .89 | 6.0 | .96 |
| 12-36 | 21 | 11 (52) | 6.5 | ||
| > 36 | 37 | 20 (54) | 7.5 | ||
| Salvage status | |||||
| First | 50 | 28 (56) | .34 | 7.5 | .32 |
| ≥ Second | 25 | 11 (44) | 4.5 | ||
| Additional chromosomal abnormalities | |||||
| No | 28 | 18 (64) | .15 | 7.5 | .49 |
| Yes | 43 | 20 (47) | 4.5 | ||
| Objective response (landmark 8 weeks) | |||||
| No | 38 | — | 9.2 | .002 | |
| Yes | 28 | — | 5.6 |
| Characteristic . | No. . | No. responding (%) . | P . | Median survival, mo . | P . |
|---|---|---|---|---|---|
| Age, y | |||||
| < 60 | 48 | 21 (44) | .09 | 6.0 | .86 |
| ≥ 60 | 27 | 18 (67) | |||
| Splenomegaly, cm bcm | |||||
| ≤ 5 | 40 | 21 (53) | .62 | 7.1 | .46 |
| > 5 | 28 | 17 (61) | 7.5 | ||
| Hemoglobin, g/dL | |||||
| < 10 | 38 | 21 (55) | .65 | 5.2 | .49 |
| ≥ 10 | 37 | 18 (49) | 5.2 | ||
| White blood cells, × 109/L | |||||
| < 30 | 38 | 22 (58) | .36 | 9.0 | .08 |
| ≥ 30 | 37 | 17 (46) | 5.4 | ||
| Platelets, × 109/L | |||||
| ≤ 50 | 25 | 10 (40) | .15 | 4.2 | .02 |
| > 50 | 50 | 29 (58) | 7.6 | ||
| % Peripheral blood blasts | |||||
| < 50 | 48 | 30 (63) | .02 | 7.6 | .18 |
| ≥ 50 | 27 | 9 (33) | 6.0 | ||
| % Bone marrow blasts | |||||
| < 50 | 35 | 20 (57) | .49 | 7.2 | .28 |
| ≥ 50 | 40 | 19 (48) | 6.2 | ||
| Blast morphology | |||||
| Lymphoid | 10 | 3 (30) | .18 | 6.8 | .20 |
| Nonlymphoid | 65 | 36 (55) | 6.5 | ||
| Time from diagnosis to blast phase, mo | |||||
| < 12 | 17 | 8 (47) | .89 | 6.0 | .96 |
| 12-36 | 21 | 11 (52) | 6.5 | ||
| > 36 | 37 | 20 (54) | 7.5 | ||
| Salvage status | |||||
| First | 50 | 28 (56) | .34 | 7.5 | .32 |
| ≥ Second | 25 | 11 (44) | 4.5 | ||
| Additional chromosomal abnormalities | |||||
| No | 28 | 18 (64) | .15 | 7.5 | .49 |
| Yes | 43 | 20 (47) | 4.5 | ||
| Objective response (landmark 8 weeks) | |||||
| No | 38 | — | 9.2 | .002 | |
| Yes | 28 | — | 5.6 |